Companies Morphogen-IX

Finding a treatment for pulmonary arterial hypertension


At present, there is no cure for pulmonary arterial hypertension (PAH).

Morphogen-IX is a start-up based on the work of Professor Nick Morrell and a team from the Department of Medicine at Addenbrooke’s Hospital, Cambridge, that is seeking to change this. It was recently acquired by Centessa Pharmaceuticals.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More